Molecular-specific effects of angiotensin II antagonists: Clinical relevance to treating hypertension?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 6, Issue 1, 2005, Pages 15-24

  Reid, John L ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Angiotensin II antagonists; Hypertension; Platelet aggregation; PPAR ; Serum uric acid; Thromboxane A2 receptor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALLOPURINOL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PROBENECID; ROSIGLITAZONE; TELMISARTAN; THROMBOXANE A2 RECEPTOR; URIC ACID; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERURICEMIA; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LUNG EDEMA; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN INDUCTION; REVIEW; STROKE; SYMPATHETIC TONE; THROMBOCYTE AGGREGATION INHIBITION; URIC ACID BLOOD LEVEL;

EID: 20444418116     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2005.002     Document Type: Review

References (99)

1. Ferrario C, Abdelhamed AI, Moore M. AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Curr Med Res Opin 2004;20:279-93.
2. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
3. McKelvie RS. The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. Expert Opin Investig Drugs 2004;13:245-53.
4. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003;25:3044-64.
5. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-ganima activity. Circulation 2004; 109:2054-7.
6. Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281:1065-70.
7. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998; 32:198-205.
8. Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J Hypertens 2001;19:561-6.
9. Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000;292:238-46.
10. Monton M, Jimenez A, Nunez A et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35:906-13.
11. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 2001; 15:301-07.
12. Fogari R, Derosa G, Mugellini A et al. Effect of losartan, irbesartan, and candesartan on platelet aggregability and fibrinolysis in type 2 diabetic hypertensive patients. (abstract). J Hypertens 2003;21(suppl 4):S85.
13. Leu HB, Charng MJ, Ding PY. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. Jpn Heart J 2004;45:623-35.
14. Serebruany VL, Malinin AI, Lowry DR et al. Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. J Cardiovasc Pharmacol 2004;43:677-84.
15. Burnier M, Pechere-Bertschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995;26: 108-15.
16. Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793-7.
17. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71.
18. Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol 1996;36:403-08.
19. Maeso R, Rodrigo E, Munoz-Garcia R et al. Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide. J Hypertens 1997;15:1677-84.
20. Schwemmer M, Sommer O, Bassenge E. Blockade of angiotensin signaling improves myocardial function in hypercholesterolemia independent of changes in eicosanoid release. Cardiovasc. Drugs Ther 2000;14:317-27.
21. Valentin JP, Jover B, Maffre M, Bertolino F, Bessac AM, John GW. Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat. Am J Hypertens 1997;10:1058-63.
22. Picard P, Chretien L, Couture R. Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat. Br J Pharmacol 1995;114:1563-70.
23. Li Z, Bosch SM, Smith TL, Diz DI. Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain. J Cardiovasc Pharmacol 1996; 28:425-31.
24. Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR, Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244-51.
25. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002; 18:1331-9.
26. Liu YH, Yang XP, Sharov VG et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99:1926-35.
27. Audoly LP, Le TH, Coffman TM. What can knockout mice contribute to an understanding of hypertension? Curr Hypertens Rep 2000;2:192-7.
28. Reid JL. The sympathetic nervous system and the renin-angiotensin system. In: Nicholls MG, Brunner H, Ikram H, Sweet CS, Walker JF (eds.). 100 Years of the Renin-Angiotensin System. Whitehouse Station: Merck & Co., Inc., 1998:163-6.
29. Reid JL. Hypertension and the brain. Br Med Bull 1994; 50:371-80.
30. Grassi G. Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options. Curr Hypertens Rep 2003;5:277-80.
31. Stroe AF, Gheorghiade M. Carvedilol: beta-blockade and beyond. Rev Cardiovasc Med 2004;5(suppl 1):S18-27:S18-S27.
32. Abraham WT, Iyengar S. Practical considerations for switching beta-blockers in heart failure patients. Rev Cardiovasc Med 2004; 5(suppl 1):S36-S44.
33. Sorrentino MJ. Beta-blockers for congestive heart failure. Compr Ther 2003;29:210-14.
34. Gavras I, Manolis AJ, Gavras H. The alpha2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens 2001;19:2115-24.
35. Majewski H, Hedler L, Schurr C, Starke K. Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II. J Cardiovasc Pharmacol 1984;6:888-96.
36. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Sympatho-inhibitory properties of various AT1 receptor antagonists. J Hypertens 2002;20(suppl 5):S3-S11.
37. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003;42:664-8.
38. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
39. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879-87.
40. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-88.
41. Kersten S,Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-4.
42. Fajas L, Auboeuf D, Raspe E et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-89.
43. Mukherjee R, Jow L, Croston GE, Paterniti JR, Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997;272:8071-6.
44. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-50.
45. Law RE, Goetze S, Xi XP et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000;101:1311-18.
46. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-97.
47. Ogihara T, Rakugi H, Ikegand H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
48. Sung BH, Izzo JL, Jr., Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34:83-8.
49. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
50. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998;41:569-76.
51. Yoshioka S, Nishino H, Shiraki T et al. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993;42:75-80.
52. Fujimoto M, Masuzaki H, Tanaka T et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004; 576:492-7.
53. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
54. Wu L, Wang R, de Champlain J, Wilson TW. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 2004; 17:749-56.
55. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003; 78:1088-91.
56. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 2003; 3:147-62.
57. Tan KT, Watson SP, Lip GY. The endothelium and platelets in cardiovascular disease: potential targets for therapeutic intervention. Curr Med Chem Cardiovasc Hematol Agents 2004; 2:169-78.
58. Kramer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90:770-6.
59. Lip GY, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J Intern Med 2001; 249:205-14.
60. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-82.
61. Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966;1:15-18.
62. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-8.
63. Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004;66:281-7.
64. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence (abstract). Hypertension 2005;45:28-33.
65. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of serum uric acid as a causal risk factor in essential hypertension (abstract). Hypertension 2005;45:18-20.
66. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-50.
67. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126-30.
68. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224:549-55.
69. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141:637-44.
70. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Seram uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973;132:401-10.
71. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136-43.
72. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072-8.
73. Alderman MH. Serum uric acid as a cardiovascular risk factor for heart disease. Curr Hypertens Rep 2001;3:184-9.
74. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
75. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17:1033-9.
76. Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347.
77. Manolis AJ, Grossman E, Jelakovic B et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000;22:1186-203.
78. Sayin T, Doven O, Akyurek O, Dincer I. Neutral effect of valsartan on serum uric acid and renal function tests. J Hum Hypertens 2001;15:435-6.
79. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-90.
80. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
81. Nikas S, Rizos E, Milionis H et al. The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide. JRAAS 2000;1:289-91.
82. Soffer BA, Wright JT, Jr., Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-17.
83. Weber MA, Byyny R-L, Pratt JH et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995;155:405-11.
84. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997; 280:839-45.
85. Roch-Ramel F, Werner D, Guisan B. Urate transport in brush-border membrane of human kidney. Am J Physiol 1994; 266:F797-F805.
86. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9.
87. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999;15 (suppl F):26F-28F.
88. Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med 2004;116:31-8, 41.
89. Sada T, Mizunu M. [Pharmacological profiles and clinical effects of olinesartan medoxomil, a novel angiotensin II receptor blocker]. Nippon Yakurigaku Zasshi 2004;124:257-69.
90. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42:333-5.
91. Smith MC, Barrows S, Meibohm A et al. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens 1995;8:1177-83.
92. Fauvel JP, Velon S, Berra N et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996;28:259-63.
93. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58:762-9.
94. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol 2000; 27:2232-6.
95. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001;16:1034-7.
96. Kamper AL, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001; 72:671-4.
97. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23:1166-79.
98. Wurzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19:1855-60.
99. Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens 2002; 20(suppl 5):S29-S31.